New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 18, 2014
07:19 EDTALPMY, MDVNMedivation, Astellas Pharma submit sNDA for XTANDI
Astellas Pharma (ALPMY) and Medivation (MDVN) announced the submission of a supplemental New Drug Application, or sNDA, to the FDA seeking approval of XTANDI capsules for the treatment of men with metastatic castration-resistant prostate cancer, or mCRPC, who have not received chemotherapy. XTANDI is currently approved for the treatment of patients with mCRPC who have previously received docetaxel chemotherapy. The sNDA application is based on the results from the Phase 3 PREVAIL trial evaluating XTANDI as compared to placebo in more than 1,700 chemotherapy-na´ve mCRPC patients. The marketing authorization application is expected to be submitted to the European Medicines Agency later this year.
News For MDVN;ALPMY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 30, 2015
09:18 EDTMDVNMedivation price target raised to $163 from $126 at Maxim
Subscribe for More Information
08:22 EDTMDVNMedivation price target raised to $163 from $126 at Maxim
Subscribe for More Information
07:24 EDTMDVNStifel to hold a bus tour
BioTrek: 2015 West Coast Healthcare Therapeutics Bus Tour travels throughout San Francisco on March 30-April 1.
March 27, 2015
06:55 EDTMDVNMedivation price target raised to $150 from $133 at Barclays
Subscribe for More Information
March 25, 2015
16:21 EDTALPMYVical in-licenses novel antifungal ASP2397 from Astellas Pharma
Subscribe for More Information
09:06 EDTMDVNMedivation price target raised to $144 from $123 at William Blair
Subscribe for More Information
07:53 EDTMDVNMedivation reported strong, positive results, says JMP Securities
JMP Securities says that the results of a study comparing Medivation's Xtandi to bicalutamide, the market leading prostate cancer medication, were strong and positive for Medivation. The firm continues to expect Xtandi to prove to be superior to bicalutamide. It expects Xtandi to generate $8B in worldwide revenue and raised its price target on Medivation to $143 from $126 while keeping an Outperform rating on the shares.
07:39 EDTMDVNMedivation price target raised to $142 from $125 at Brean Capital
Brean Capital raised its price target on Medivation to $142 from $125 following the presentation of additional Phase 2 TERRAIN trial data in metastatic castration-resistant prostate cancer and final OS data from the Phase 3 PREVAIL trial in chemo-naive mCRPC. The firm remains optimistic by consistent and positive data and reiterated its Buy rating on Medivation shares.
07:02 EDTMDVNMedivation price target raised to $148 from $130 at JPMorgan
Subscribe for More Information
March 24, 2015
07:07 EDTMDVN, ALPMYAstellas Pharma and Medivation report data from Phase 2 Terrain trial
Subscribe for More Information
March 20, 2015
09:06 EDTALPMYAmgen submits application for marketing approval for RepathaTM in Japan
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use